ClinicalTrials.gg
CompletedNCT01529840Updated Jan 18, 2017

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

A Phase 3 interventional study of somatropin and somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.

Enrollment
14th of 15
24 · median 51
Started
1990
the only one that year
Phase 3
8 of 23
none open now
Registered
7th of 23
by date

Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 1990, is one of 8 in phase 3, and was the 7th registered.

Genetic Diseases, Inborn

584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.

03

Conditions studied

  • Genetic Disorder
  • Noonan Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participation in the original S/GHD/004/NOO trial or following the protocol for S/GHD/004/NOO without being randomised in the trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Low dose 33 mcg/kg/day

    Drug: somatropin

  • Experimental
    High dose 66 mcg/kg/day

    Drug: somatropin

Interventions

  • Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

  • Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

06

What researchers measure

Primary outcomes

  1. Change in height SDS (Standard Deviation Score) from start of treatment to final height (referenced to normal population)

Secondary outcomes

  1. Final height SDS

  2. Change in height SDS from start of treatment to final height (referenced to Noonan population)

  3. Height velocity

  4. Change in height velocity

  5. Sitting height

  6. Number and proportion of subjects with final height SDS above -2 SDS

  7. Adverse events

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Göteborg, 416 85, Sweden
08

References and documents

Publications

  • Osio D, Dahlgren J, Wikland KA, Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr. 2005 Sep;94(9):1232-7. doi: 10.1111/j.1651-2227.2005.tb02081.x. PubMed 16203673 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1990, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2012
First posted
Feb 9, 2012
Start
Jun 1990
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01529840
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Jun 1990
Primary completion
Sep 2005
Completion
Sep 2005
Last update
Jan 18, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion